2
Clinical Trials associated with Chikungunya (Protinhi)A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to 18 Years) and Adults (18 Years or more than)
A Phase I Randomized Single Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of Chikungunya Vaccine (Inactivated) of HBI when administered by two different dosage schedules to Healthy Subjects of 19 to 49 Years of age.
100 Clinical Results associated with Chikungunya (Protinhi)
100 Translational Medicine associated with Chikungunya (Protinhi)
100 Patents (Medical) associated with Chikungunya (Protinhi)
100 Deals associated with Chikungunya (Protinhi)